Science and the New Zealand sector

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway, not a general licence to use cannabis. The legal route to access is a prescription from a medical practitioner, and what is dispensed must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The most common misunderstanding is that “legal medicinal cannabis” means a patient can legally smoke raw plant material or buy unregulated products. In New Zealand, the legal item is a manufactured pharmaceutical; even dried flower, when prescribed, is dispensed through a pharmacy under the Medicinal Cannabis Scheme, not through a dispensary or retail outlet.

Science and the New Zealand sector: what the scheme governs

The Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and fully implemented on 1 April 2020, is administered by the Medicinal Cannabis Agency (MCA), a unit within Medsafe. The scheme allows medical practitioners to prescribe cannabis-based products that meet GMP standards and have been approved by the Ministry of Health. It does not legalise recreational use, nor does it allow a patient to grow, possess, or use raw plant material outside a prescription.

The Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the legal framework. Under the scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP standards and has been notified to the Ministry of Health. The scheme does not legalise smoking raw plant material, and it does not allow a person to grow their own plants for therapeutic use. Items are dispensed through a pharmacy, not a dispensary or a retail shop. Medsafe runs the MCA, which licenses cultivators, manufacturers, and suppliers, and maintains a public register of notified products. As of the 2020 amendments to the Misuse of Drugs Act, the scheme came into full effect, and the NZ Formulary lists cannabis products that can be prescribed. Personal decisions about a specific item or dose should be directed to a qualified prescriber or pharmacist.

The legal framework

A prescription is the only legal route to access medicinal cannabis. Products must be manufactured to GMP standards and notified to the Ministry of Health before they can be prescribed. The MCA issues licences for cultivation, manufacture, and supply under the Misuse of Drugs Act 1975. The scheme’s key legal point: it creates a prescription pathway for manufactured pharmaceuticals, not a right to possess or use raw cannabis.

What counts as medicinal cannabis

Medicinal cannabis is a pharmaceutical, not a herbal remedy. Under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, a medical practitioner can prescribe a cannabis-based product if they believe it is clinically appropriate. The item must be a controlled drug approved by Medsafe and must meet GMP standards. This is the key legal boundary: the scheme does not legalise raw plant material for personal use; it legalises a prescription pathway for manufactured products.

How the New Zealand scheme works

The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. It is administered by the MCA, which sits within Medsafe. The scheme allows medical practitioners to prescribe cannabis-based products that meet GMP standards and have been approved by the Ministry of Health. A prescription from a medical practitioner is the only legal route to access these items. The raw flower, when prescribed, is dispensed through a pharmacy, not a dispensary, and patients cannot legally smoke it or buy it from unregulated sources.

The prescription pathway

The patient pathway begins with a consultation with a medical practitioner (GP or specialist) who can prescribe under the Misuse of Drugs Act. The practitioner must consider the patient’s condition, previous treatments, and potential risks; they are not required to be a cannabis specialist, but they must be satisfied that conventional treatments have failed or are unsuitable. The script is written for a specific product (for example, Tilray 10:10 oil) with a dose and administration route; it is not a general “cannabis prescription.” The item is dispensed at a licensed pharmacy, not a dispensary or retail outlet. Under the Medicinal Cannabis Scheme, products must meet GMP standards and be approved by the Ministry of Health. Patients cannot legally possess or use raw cannabis flower unless it is prescribed and dispensed through a pharmacy. The NZ Formulary lists cannabis products with monographs; prescribers should follow the NZ Formulary guidance. The Misuse of Drugs Act 1975 was amended in 2018 to allow therapeutic use.

What is available and how to compare options

Products available in New Zealand include: Tilray 10:10, Tilray 25:25, Medleaf THC25, Medleaf THC10:CBD10, Medleaf CBD100, NUBU 100 (CBD isolate oil), Cann Group THC20, Cann Group CBD100, Spectrum Red No. 1, Spectrum Yellow No. 2, LGP Classic 10:10 and 20:5, Helius THC25, Helius CBD100, MedReleaf Avidekel, Bedrocan, Bediol, Bedrolite, Cannabisol 100, Eve CBD flower, Aurora Sedaprem, Aurora Vespucci, and others. Not all are available at all times; availability changes with supply and regulatory approval.

Products are classified by the ratio of THC to CBD, not by brand strength. Patients should ask their prescriber for an option matching their symptom profile, not a brand. The only legal forms are manufactured pharmaceuticals: oils, capsules, dried flower for vaporisation, and some oromucosal sprays.

What the evidence says and does not say

The NZ Formulary lists medicinal cannabis products with official monographs, and prescribers use it as the reference for dosing and product selection. Healthify (previously Health Navigator) is the official NZ health information resource; it includes patient-oriented summaries of medicinal cannabis and its risks. Medsafe approves finished items for sale in New Zealand under Section 29 of the Misuse of Drugs Act. Products must meet GMP and contain only approved active ingredients (THC, CBD, or both). The MCA licenses companies to cultivate, manufacture, supply, or import controlled drugs for therapeutic use. It does not approve individual prescriptions.

Safety, side effects and daily life

Driving and impairment

Driving while impaired by any prescribed product remains illegal. Anyone using a THC-containing item must not drive or operate heavy machinery until they know how it affects them. Patients should discuss sedation and cognitive effects with their prescriber before starting treatment.

Adverse effects and interactions

Adverse effects can include dizziness, fatigue, and changes in mood or appetite. Report any concerning symptoms to the prescribing practitioner. Patients should also discuss potential interactions with other medicines before starting treatment.

What the scheme does not allow

The scheme does not allow smoking raw plant material. Dried flower is available only as a prescribed pharmaceutical, dispensed for vaporisation.

Where to go next

The focused guides in this section cover the patient pathway, the evidence, the available options, and safety in daily life, each in depth. For personal decisions about a specific product or dose, speak to a qualified prescriber or pharmacist.